The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HURA | -54.86% | -99.83% | -72.15% | -65% |
| S&P | +14.49% | +91.09% | +13.83% | +17% |
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 17.6% |
| Market Cap | $97.41M | 1204.2% |
| Market Cap / Employee | $5.13M | 0.0% |
| Employees | 19 | 0.0% |
| Net Income | -$9.52M | -309.8% |
| EBITDA | -$5.96M | -151.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.51M | 73.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.56M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -152.10% | 81.4% |
| Return On Invested Capital | -1066.27% | 221.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.25M | -225.9% |
| Operating Free Cash Flow | -$6.25M | -226.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.68 | -0.99 | -0.79 | 10.17 | -689.61% |
| Price to Tangible Book Value | -43.59 | -0.99 | -0.79 | 10.17 | -116.85% |
| Enterprise Value to EBITDA | -3.98 | -27.29 | -19.19 | -15.38 | 79.55% |
| Return on Equity | -2345.6% | -190.7% | -244.2% | -287.9% | -45.65% |
| Total Debt | $24.61M | $0.20M | $0.16M | $0.56M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
